BC Innovations | Oct 31, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 30 genomic loci could help predict the risk of schizophrenia. Genome-wide association studies in 47,559 schizophrenia patients and 70,936 healthy volunteers identified associations between the disease and SNPs on 30 loci,...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

Cardiovascular disease INDICATION: Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31 levels were higher in atrial myocytes from AF patients and in the left ventricle of a...
BC Innovations | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
BC Innovations | Oct 6, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neuronal nitric oxide synthase 1 (NOS1; nNOS) Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based nNOS inhibitors that could help treat neuropathic pain....
BC Innovations | Dec 9, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Discs large homolog 4 (DLG4; PSD95); neuronal nitric oxide synthase 1 (NOS1; nNOS) Rodent studies suggest that inhibiting interactions between nNOS and PSD95 in...
BC Week In Review | Nov 15, 2010
Clinical News

NXN-188: Phase II data

The double-blind, U.S. Phase II Study 204 trial in 174 patients with moderate to severe acute migraine headache without aura showed that a single dose of oral 600 mg NXN-188 missed the primary endpoint of...
BC Innovations | Mar 5, 2009
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Musculoskeletal disease Duchenne muscular dystrophy (DMD) Dystrophin (DMD); nitric oxide synthase 1 (neuronal) (NOS1; nNOS) Ex vivo and mouse studies suggest...
BC Innovations | Nov 6, 2008
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Fatigue Neuronal nitric oxide synthase (nNOS) Studies in mice suggest that increasing levels of sarcolemma-localized nNOS could be useful for lowering...
BC Innovations | Mar 27, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras; nitric oxide synthase 3 (NOS3; eNOS) A study in cell culture and mice suggests that antagonizing eNOS might treat...
BioCentury | Nov 19, 2007
Emerging Company Profile

Corporate Profile

NeurAxon Inc. Waltham, Mass. Technology: Neuronal nitric oxide synthase ( nNOS ) inhibitors Disease focus: Neurology Clinical status: Phase I Founded: 2004 by Suman Rakhit, John Andrews and Shawn Maddaford University collaborators: University of Arizona Corporate partners:...
Items per page:
1 - 10 of 13